Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT05887661

Goal-directed LCVP Based on HP in Laparoscopic Hepatectomy

Led by The First Affiliated Hospital with Nanjing Medical University · Updated on 2024-11-12

100

Participants Needed

1

Research Sites

208 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this clinical trial is to learn about goal-directed LCVP based on hypovolemic phlebotomy (HP) in laparoscopic hepatectomy. The main questions it aims to answer are: 1. The safety and feasibility of HP 2. To evaluate whether HP can reduce perioperative blood transfusion ratio Participants undergoing liver resection with HP was performed by the anesthesiologist. Blood was withdrawn approximately 30 min prior to the initiation of liver parenchymal transection from central venous. The aim was to maintain the CVP between 0 to 5 cmH2O. HP volume was 5-10 mL/kg of patient body weight, generally. Participants in control group undergoing liver resection without HP.

CONDITIONS

Official Title

Goal-directed LCVP Based on HP in Laparoscopic Hepatectomy

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Clinical diagnosis of Hepatocellular Carcinoma
  • Preference for laparoscopic hepatectomy and patient agreement
Not Eligible

You will not qualify if you...

  • Age less than 18 years
  • Pregnancy
  • Refusal of blood product transfusion
  • Active cardiac conditions including unstable coronary syndromes, decompensated heart failure, significant arrhythmias, severe valvular disease, or history of congestive heart failure
  • History of significant cerebrovascular disease
  • Restrictive or obstructive pulmonary disease
  • Uncontrolled hypertension
  • Renal dysfunction with glomerular filtration rate less than 60 mL/min
  • Hemoglobin less than 100 g/L
  • Abnormal coagulation values (INR greater than 1.5 not on warfarin and/or platelet count less than 100 x 10^9/L)
  • Evidence of hepatic metabolic disorder (bilirubin greater than 35 mmol/L)
  • Presence of active infection
  • Preoperative autologous blood donation
  • Use of erythropoietin during the index hospitalization not allowed

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

The First Affiliated Hospital of Nanjing Medical University

Nanjing, Jiangsu, China, 210029

Actively Recruiting

Loading map...

Research Team

S

Shijiang Liu, MD

CONTACT

Y

Yue Wang

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here